Skip to main content
SpringerLink
Log in

Afamelanotide to be evaluated as a Highly Specialised Technology

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Clinuvel Pharmaceuticals. NICE ENGLAND UPDATE ON SCENESSE(R). Media Release : 2 May 2017. Available from: URL: http://www.clinuvel.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afamelanotide to be evaluated as a Highly Specialised Technology. PharmacoEcon Outcomes News 778, 35 (2017). https://doi.org/10.1007/s40274-017-4012-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4012-x

Search

Navigation